Brooks Laboratories Ltd

Brooks Laboratories Ltd’s shares declined sharply to a new 52-week low of Rs.54.2 on 19 Mar 2026, marking a significant drop amid broader market weakness and sectoral pressures. The stock underperformed the Pharmaceuticals & Biotechnology sector and the wider market, reflecting ongoing concerns about its long-term performance and valuation metrics.

Brooks Laboratories Ltd has touched a new 52-week low of Rs.54.62 today, marking a significant decline in its stock price amid broader market movements. The stock has underperformed its sector and key benchmarks, reflecting ongoing concerns about its financial metrics and market positioning.

Brooks Laboratories Ltd has touched a new 52-week low of Rs.57 today, marking a significant decline amid ongoing downward momentum. The stock has underperformed its sector and broader market indices, reflecting persistent pressures on its valuation and performance metrics.

Brooks Laboratories Ltd has reached a new 52-week low of Rs.57.06, marking a significant decline in its stock price amid broader market weakness and sector underperformance. The stock’s recent performance reflects ongoing challenges in its financial metrics and market positioning within the Pharmaceuticals & Biotechnology sector.

Brooks Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Brooks Laboratories Ltd has reached a new 52-week low of Rs.57.84, marking a significant decline amid broader market weakness and ongoing challenges within the Pharmaceuticals & Biotechnology sector. The stock’s recent performance reflects a continuation of downward momentum, with a three-day losing streak culminating in a 5.27% drop over this period.

Brooks Laboratories Ltd has reached a new 52-week low of Rs.58.25 today, marking a significant decline in its share price amid ongoing market pressures and a series of underwhelming performance metrics. The stock’s recent trajectory reflects a challenging period for the company within the Pharmaceuticals & Biotechnology sector.

Brooks Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Brooks Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from a very attractive to a fair valuation grade. This change, coupled with its current financial metrics and market performance, offers investors a nuanced perspective on the stock’s price attractiveness relative to its historical averages and peer group.

Brooks Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 16 February 2026, driven primarily by a marked improvement in valuation metrics. Despite ongoing challenges in financial trends and quality parameters, the stock’s attractive valuation and positive technical signals have prompted a reassessment of its market stance.

Brooks Laboratories Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 11 Feb 2026, reflecting a complex interplay of financial performance, valuation shifts, and technical indicators. Despite some positive quarterly earnings growth, the company’s overall fundamentals and market positioning have deteriorated, prompting a reassessment of its investment appeal within the Pharmaceuticals & Biotechnology sector.

Brooks Laboratories Ltd has experienced a notable shift in its valuation parameters, moving from a very attractive to a fair valuation grade, reflecting evolving market perceptions amid a challenging pharmaceutical sector landscape. Despite a recent uptick in share price, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now align more closely with sector averages, signalling a recalibration of investor expectations.

Brooks Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, surged to hit its upper circuit limit on 9 Feb 2026, registering a maximum daily gain of 19.99%. The stock closed at ₹73.11, marking a significant turnaround after two consecutive days of decline, driven by robust buying interest and heightened volatility.

Brooks Laboratories Ltd., a micro-cap pharmaceutical contract manufacturer, reported a troubling third quarter for FY2026 with net sales plunging 29.34% quarter-on-quarter to ₹16.57 crores, marking the weakest quarterly revenue performance in recent history. Whilst consolidated net profit stood at ₹5.50 crores, this figure was artificially inflated by significant tax write-backs rather than genuine operational improvements, raising serious questions about the sustainability of the company's profitability trajectory.

Brooks Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 December 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 06 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.